Oncology Experts Preview Top Abstracts From AUA 2025

Ahead of the 2025 American Urological Association (AUA) Annual Meeting, OncLive® asked leading oncologists in the space to share what presentations they are most excited to learn more about during the meeting and why.

This exclusive preview features insights from the following:

• Roberto Contieri, MD, who is a urologist at IRCCS Istituto Nazionale Tumori, Fondazione "G. Pascale" in Naples, Italy;
• Alireza Ghoreifi, MD, who is a Society of Urologic Oncology fellow at Duke University in Durham, North Carolina; and
• Mark D. Tyson, II, MD, MPH, who is a urologist at Mayo Clinic in Phoenix, Arizona.

Contieri’s list:

Roberto Contieri, MD

Abstract PD12-01: Treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer with UGN-102: ongoing results from a single-arm, open-label, phase 3 trial (ENVISION)

Abstract MP15-05: Treatment of low-grade intermediate-risk non-muscle invasive bladder cancer with UGN-102: long-term outcomes of the OPTIMA II study

“These abstracts are particularly relevant as they reflect the growing trend toward treatment deintensification for low-grade bladder cancer—a shift aiming to reduce procedural morbidity without compromising oncologic outcomes. The promising efficacy and safety profile of UGN-102 may support a paradigm shift away from repetitive transurethral resection of bladder tumors toward a less invasive, yet effective, intravesical therapy for low-grade, intermediate-risk non–muscle-invasive bladder cancer [NMIBC].”

Trial in progress: PIVOT-006- A phase 3, randomized study of adjuvant intravesicalcretostimogene grenadenorepvec versus surveillance for the treatment of intermediate-risk non-muscle invasive bladder cancer

“There are also ongoing studies in the intermediate-risk NMIBC setting focusing on adjuvant therapy. One of the most noteworthy is the updated PIVOT-006 trial [NCT06111235], which addresses a critical evidence gap by prospectively evaluating adjuvant therapy vs surveillance in a population for whom optimal management remains undefined. The use of cretostimogene grenadenorepvec, an oncolytic viral agent, introduces a novel biological mechanism and may redefine the standard of care.”

Trial in progress: BOND-003 cohort P- A multi-national, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high-risk, papillary only, BCG-unresponsive non-muscle invasive bladder cancer

“Regarding the use of cretostimogene grenadenorepvec, the results of the [phase 3] BOND-003 study [NCT04452591] are also of interest, as this trial investigates the agent in patients with BCG-unresponsive disease. In this setting, several new therapies have emerged in recent years, reshaping the treatment landscape and offering patients the opportunity to preserve their bladder.”

Abstract PD12-13: Interim analysis of light-activated TLD-1433 in a phase II clinical study of BCG-unresponsive non-muscle invasive bladder cancer carcinoma in-situ

“This abstract is innovative as it explores a novel, non-surgical modality—light-activated intravesical photodynamic therapy with TLD-1433—for BCG-unresponsive NMIBC with carcinoma in situ [CIS]. The technology introduces a mechanistically distinct approach with promising efficacy and sustained responses, potentially expanding the therapeutic landscape beyond radical cystectomy.”

Ghoreifi’s list:

Alireza Ghoreifinejadian, MD

Abstract IP02-02: The computational histology artificial intelligence (CHAI) biomarker enhances risk stratification of high-grade Ta non-muscle invasive bladder cancer in a multicenter cohort: comparison to 2024 AUA guidelines

"In this interesting study of 250 HG-Ta bladder cancer cases, the Correlative Histologic Artificial Intelligence [CHAI] biomarker stratified risk of high-grade recurrence independently of AUA risk classification. These findings showed that CHAI may serve as an adjunctive tool to augment AUA risk stratification by providing additional clinical outcome data to support decision-making and patient counseling."

MP05-20: Perioperative outcomes of consolidative surgery following immunotherapy with pembrolizumab plus enfortumab vedotin for advanced urothelial cancer1

"In a cohort of 17 patients with advanced nonmetastatic urothelial carcinoma— including 11 with bladder cancer and 6 with upper tract urothelial cancer—who underwent consolidative surgery following immunotherapy with enfortumab vedotin-ejfv [Padcev] plus pembrolizumab [Keytruda], the pathologic complete response rate was [60]%...Surgery in this setting appeared technically feasible, with no intraoperative complications reported."

PD12-01: Treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer with UGN-102: ongoing results from a single-arm, open-label, phase 3 trial (ENVISION)2

"A total of 240 patients were enrolled in the trial. Treatment with UGN-102 resulted in a complete response [CR] rate of 79.6%. Among those who achieved an initial CR, 76.4% remained disease-free at 12 months."

IP12-14: Efficacy and safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for treatment of low-grade upper tract urothelial cancer (LGUTUC): ENLIGHTED phase 3 study3

"In this abstract, among 33 patients who completed induction Padeliporfin VTP therapy, a CR rate of 78.8% and a partial response rate of 18.2% were achieved. The rate of grade 3 [serious] adverse effects was 9.2%."

IP24-36: Undetectable circulating tumor DNA post radical cystectomy for bladder cancer may be amendable to a less intense imaging surveillance protocol

"[This is an] Interesting study on the practical value of circulating tumor DNA [ctDNA] in patients with bladder cancer. The findings showed that patients with undetectable ctDNA may safely follow less frequent surveillance."

P27-04: Prospective COTRIMS (COlogne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial — final results

"Current AUA guidelines recommend consideration of primary RPLND for patients with pure seminoma and lymph nodes measuring [no more than] 3 cm. The findings of this study support expanding the eligibility criteria to include patients with lymph node metastases up to 5 cm."

Tyson’s list:

Mark D. Tyson, II, MD, MPH

P2s: Practice-changing, paradigm-shifting clinical trials in urology: BOND-003 cohort C- phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ

“BOND-003 cohort C is an important study of an oncolytic immunotherapy [cretostimogene grenadenorepvec] in patients with BCG-unresponsive CIS. This study explores the potential for bladder-sparing outcomes through intravesical delivery of a novel agent designed to selectively replicate in and destroy cancer cells while stimulating a local immune response. Results to date have suggested the drug has excellent tolerability and durability. Cohort P is a prospective evaluation of cretostimogene grenadenorepvec in patients with high-grade, papillary-only NMIBC—a group that has historically been underrepresented in clinical trials. This study has the potential to inform future clinical trial design and treatment guidelines for patients who lack CIS but remain at high risk for disease progression.”

References

1. Ghoreifi A, Hoimes C, Ramalingham S, et al. Perioperative outcomes of consolidative surgery following immunotherapy with pembrolizumab plus enfortumab vedotin for advanced urothelial cancer. J Urol. 2025;213(5s):e140. doi:10.1097/01.Ju.0001109748.46743.Aa.20
2. Prasad SM, Shishkov D, Vmihaylov N, et al. Treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer with UGN-102: ongoing results from a single-arm, open-label, phase 3 trial (ENVISION). J Urol. 2025;213(5s):e387. doi:10.1097/01.Ju.0001109848.08748.9e.01
3. Margulis V, Kaufman R, Marcq G, et al. Efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) for treatment of low-grade upper tract urothelial cancer (LGUTUC): ENLIGHTENED phase 3 study. J Urol. 2025;213(5s):e647. doi:10.1097/01.Ju.0001109940.79528.1b.14